BMS completes Amira deal, gaining a key fibrosis programme
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has completed its acquisition of privately held Amira Pharmaceuticals, a small-molecule company focused on inflammatory and fibrotic diseases for $325 million in cash plus milestones up to $150 million, gaining access to two research programmes including an early-stage lung fibrosis programme.